Cart
sales@molnova.com
Tadocizumab
CAS No. 339086-80-5
Tadocizumab( —— )
Catalog No. M36788 CAS No. 339086-80-5
Tadocizumab (C4G1) is a humanized monoclonal antibody targeting integrin αIIbβ3 with antiplatelet and antithrombotic activity that blocks the platelet αIIbβ3 integrin interac- with brinogen and bronectin, and can be used in the study of cardiovascular disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 687 | In Stock |
|
| 10MG | 937 | In Stock |
|
| 25MG | 1416 | In Stock |
|
| 50MG | 1832 | In Stock |
|
| 100MG | 2502 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTadocizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionTadocizumab (C4G1) is a humanized monoclonal antibody targeting integrin αIIbβ3 with antiplatelet and antithrombotic activity that blocks the platelet αIIbβ3 integrin interac- with brinogen and bronectin, and can be used in the study of cardiovascular disease.
-
DescriptionTadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorIntegrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number339086-80-5
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. S Kaku, et al. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys. Thromb Haemost. 1996 Apr;75(4):679-84.?
molnova catalog
related products
-
ATN-161 trifluoroace...
ATN-161 trifluoroacetate salt is a novel integrin α5β1 antagonist that inhibits angiogenesis and growth of liver metastases in a murine model.The combination of ATN-161 plus 5-FU significantly reduces tumor cell proliferation compared to control and single-agent therapy.
-
SF0166
SF0166 is a topically administered αvβ3 integrin antagonist, inhibits integrin-ligand interactions with IC50 of 0.6 nM to 13 nM for human αvβ3, αvβ6, and αvβ8.
-
TBC3486
A potent, selective, non-peptidic integrin α4β1 (VLA-4) antagonist with IC50 of 9 nM.
